Proposal for Rapamycin (Sirolimus, Selleckchem S1039)

Overview of Therapeutic Candidate:
Rapamycin, also known as Sirolimus (Selleckchem S1039), is a macrolide compound originally isolated from the soil bacterium Streptomyces hygroscopicus. As a natural product with a complex macrocyclic lactone structure, rapamycin was discovered in the 1970s and quickly advanced as an immunosuppressive agent due to its potent inhibitory effects on cell proliferation. It belongs to the class of mTOR inhibitors and has been widely used both clinically and experimentally as an immunosuppressant in organ transplantation and as an anticancer agent. This class of compounds operates by modulating cell growth, proliferation, and metabolic response through downregulation of the mechanistic target of rapamycin complex 1 (mTORC1). Over the past few decades, rapamycin’s pharmacological profile has been completely characterized, including its well‐understood binding to the intracellular protein FKBP12 (FK binding protein 12). The rapamycin–FKBP12 complex then interacts with mTORC1, impeding its kinase activity. Historically, this compound has been used predominantly in renal transplantation to prevent rejection and in oncology settings to suppress tumor growth and proliferation. Its established use in these areas has built a substantial safety and pharmacokinetic database that supports its repurposing potential in other diseases. Given that idiopathic pulmonary fibrosis (IPF) is characterized by hyperactive fibroblast proliferation, excessive extracellular matrix (ECM) deposition, and increased myofibroblast contractility, the use of rapamycin as an mTORC1 inhibitor is mechanistically compelling. By attenuating protein synthesis pathways and cell growth signals, rapamycin may counteract the pathogenic cellular processes responsible for progressive fibrotic remodeling in the lung (Lawrence & Nho, 2018).

Therapeutic History:
Rapamycin has an extensive therapeutic history that spans its initial application as an immunosuppressant in kidney transplantation to its more recent exploration in oncology, where its antiproliferative properties have been harnessed in various cancers. In the context of pulmonary diseases, rapamycin has been evaluated in several preclinical studies for its antifibrotic potential. Experimental investigations have demonstrated that rapamycin can reduce fibroblast proliferation and suppress extracellular matrix protein synthesis, including collagens and fibronectin, which are primary drivers of fibrosis in conditions such as IPF (Gao et al., 2013). Notably, rapamycin has been shown to decrease markers of fibroblast activation such as α-smooth muscle actin (α-SMA) and collagen levels in in vitro models, as well as attenuate fibrotic remodeling in various rodent models of lung fibrosis (Lawrence & Nho, 2018). In clinical practice, although rapamycin is not yet approved for treating IPF, its pathway and mode of action have led to several clinical investigations. For instance, ClinicalTrials.gov lists at least seven trials evaluating rapamycin (sirolimus) in the context of idiopathic pulmonary fibrosis or lung fibrosis, including a completed pilot study (ClinicalTrials.gov, 2011). Nevertheless, the results from those studies remain limited in detail, and while rapamycin’s preclinical antifibrotic potential is well documented, its analysis in pulmonary fibrosis has been met with mixed outcomes, particularly due to incomplete inhibition of downstream signals critical for full antifibrotic efficacy (Molina-Molina et al., 2018).

Mechanism of Action:
At the molecular level, rapamycin acts as an allosteric inhibitor of mTORC1. Its mechanism begins with binding to FKBP12, which then interacts with a specific rapamycin-binding (FRB) domain on mTOR. This interaction primarily inhibits mTORC1, a multi-protein complex that includes essential components such as Raptor, mLST8, PRAS40, and DEPTOR. mTORC1 plays a central role in regulating protein synthesis, cell growth, metabolism, and autophagy by phosphorylating targets such as p70S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). Phosphorylation of p70S6K enhances protein synthesis by promoting ribosomal biogenesis, whereas phosphorylation of 4E-BP1 releases its inhibitory hold on eIF4E, thus facilitating cap-dependent mRNA translation. Rapamycin effectively suppresses the phosphorylation of p70S6K, which correlates with reduced protein synthesis and cell proliferation. However, it is well documented that 4E-BP1 phosphorylation is less sensitive to rapamycin, leading to an incomplete blockade of mTORC1 downstream signaling pathways that are essential for the translation of specific mRNAs, including those encoding collagen and other ECM proteins (Woodcock et al., 2019). In the context of IPF, hyperactive mTOR signaling in fibroblasts promotes their proliferation and differentiation into myofibroblasts, which are the effector cells responsible for excessive collagen secretion and ECM deposition, the hallmarks of IPF pathology. Studies investigating the role of mTOR in pulmonary fibrosis have demonstrated that TGF-β1, a potent profibrotic cytokine, induces mTOR activation and subsequently enhances collagen synthesis via the mTOR/p70S6K signaling pathway (Gao et al., 2013). Additionally, evidence suggests that while rapamycin can moderately reduce markers such as collagen III and fibronectin production in primary human lung fibroblasts, its inability to completely inhibit 4E-BP1 phosphorylation may limit its overall antifibrotic efficacy (Eley, 2018). Thus, rapamycin’s molecular interactions target several key pathways implicated in fibroblast activation, yet the differential sensitivity of mTORC1 substrates poses a challenge in achieving total suppression of the profibrotic signaling cascade (Lawrence & Nho, 2018; Woodcock et al., 2019).

Expected Effect:
The central hypothesis posits that rapamycin, by selectively inhibiting mTORC1, will suppress the progression of IPF through several mechanisms. First, by dampening mTORC1 activity, rapamycin is expected to reduce fibroblast proliferation effectively. Fibroblasts in IPF exhibit hyperactive proliferation due to elevated mTOR signaling, and rapamycin, by causing G₁ arrest, may limit the expansion of these cells (Lawrence & Nho, 2018). Secondly, rapamycin’s inhibition of the mTOR/p70S6K pathway should lead to a marked reduction in the synthesis of ECM proteins such as collagen and fibronectin. In vitro studies using primary human lung fibroblasts have demonstrated that rapamycin significantly decreases TGF-β1-induced production of collagen III and fibronectin at both the transcriptional and translational levels, which is critical since these ECM components are responsible for the scarring and structural disruption characteristic of IPF (Gao et al., 2013). Thirdly, an additional beneficial effect may be the attenuation of myofibroblast contractility. Myofibroblasts are characterized by their contractile phenotype, largely mediated by α-SMA, which contributes to tissue stiffness and further aberrant remodeling of the lung architecture. Although rapamycin has been shown to reduce α-SMA expression in some studies, its effectiveness in completely reversing myofibroblast contractility remains less certain due to the incomplete inhibition of the 4E-BP1 axis (Eley, 2018). In three-dimensional collagen gel contraction assays, it is anticipated that rapamycin will reduce the contractile force exerted by activated myofibroblasts, thereby preserving lung parenchymal integrity and function. Importantly, the targeted reduction in ECM production is expected to result in decreased collagen deposition in the lung, mitigating the fibrotic progression observed in IPF. The targeting of hyperactive fibroblast and myofibroblast populations in IPF is particularly relevant because these cells are known to express high levels of mTOR signaling components and profibrotic cytokines, creating a microenvironment that sustains fibrosis (Lawrence & Nho, 2018). Thus, based on mechanistic studies and preclinical data in both cell culture and animal models, rapamycin is expected to exert a dose-dependent antifibrotic effect in IPF by suppressing fibroblast proliferation, reducing synthesis of key ECM proteins, and attenuating the contractile phenotype of myofibroblasts (Molina-Molina et al., 2018; Patel et al., 2012).

Overall Evaluation:
In summary, rapamycin represents a highly promising therapeutic candidate for the treatment of idiopathic pulmonary fibrosis due to its well-characterized mechanism of action, established clinical use in other diseases, and supportive preclinical data. Rapamycin’s origins as a natural macrolide have paved the way for its extensive use as an immunosuppressant and antiproliferative agent. Its role as an allosteric mTORC1 inhibitor, through the formation of an FKBP12-rapamycin complex, directly interferes with the mTOR pathway. This interference reduces phosphorylation of targets such as p70S6K, thereby decreasing protein synthesis and cell proliferation – processes that are pathologically upregulated in IPF fibroblasts (Lawrence & Nho, 2018; Gao et al., 2013). However, despite its strengths, a key limitation of rapamycin lies in its partial inhibition of mTORC1, particularly its limited effect on 4E-BP1 phosphorylation. Since the mTORC1/4E-BP1 axis appears critical for collagen synthesis and the profibrotic phenotype, the rapamycin-induced incomplete blockade of this pathway may contribute to suboptimal antifibrotic effects in some settings (Woodcock et al., 2019; Eley, 2018). This nuance suggests that while rapamycin can reduce fibroblast proliferation and certain ECM components, it may not completely reverse the fibrogenic processes, especially those driven by TGF-β1. Preclinical studies have provided compelling evidence that rapamycin reduces collagen production and ameliorates fibrosis in rodent models; nevertheless, some investigations note that rapamycin had no significant effect on TGF-β1-induced collagen deposition in specific fibroblast populations (Eley, 2018; Gao et al., 2013). Moreover, from a clinical perspective, pilot studies such as NCT01462006 have been initiated to explore sirolimus’s effects in IPF patients; yet, the absence of robust clinical outcome data and mixed preclinical signals indicate that its efficacy may be limited when administered as monotherapy. Safety concerns also warrant consideration. Although rapamycin has a well-established safety profile in transplant patients and cancer therapy, there are documented risks of pulmonary toxicity, including interstitial pneumonitis and other adverse pulmonary reactions, albeit infrequently (Aparicio et al., 2009). This complicates its repurposing for IPF, where the lung is the primary organ at risk.

Nevertheless, the strengths of rapamycin include its extensive mechanistic and pharmacological characterization, the breadth of preclinical data supporting its antifibrotic effects in vitro and in vivo, and its ability to modulate several key pathological processes in IPF. Its immunosuppressive and antiproliferative properties, along with its influence on fibroblast-to-myofibroblast conversion and ECM synthesis, clearly align with the therapeutic needs of IPF. Given the complex pathophysiology of IPF, where multiple signaling pathways contribute to persistent fibrogenesis, therapeutic strategies that target a central node such as mTOR are rational, even if monotherapy with rapamycin might require dose optimization or combination with other antifibrotic agents to achieve maximal clinical benefit (Molina-Molina et al., 2018; Platé et al., 2020). Some studies even suggest that dual mTORC1/mTORC2 inhibitors or ATP-competitive mTOR inhibitors, which more comprehensively inhibit the mTOR pathway including its effect on 4E-BP1, may offer superior antifibrotic efficacy compared to rapamycin alone (Woodcock et al., 2019). This observation highlights a potential weakness: rapamycin's inability to fully block all fibrogenic signaling cascades may limit its utility unless used in combination therapies or in populations where mTORC1 is the predominant driver of fibrosis.

In conclusion, while rapamycin holds significant promise as a repurposed drug candidate for the treatment of idiopathic pulmonary fibrosis based on its ability to interfere with mTOR-mediated fibroblast proliferation, ECM protein synthesis, and myofibroblast differentiation, careful attention must be paid to its incomplete inhibition of certain downstream mTOR targets and potential pulmonary toxicities. The preclinical data are encouraging, especially in terms of mechanistic insights and dose-dependent effects in vitro, but clinical validation remains critical. Future directions should include well-powered clinical trials with appropriate biomarkers to assess antifibrotic efficacy, as well as exploration of combination regimens that may overcome the limitations of rapamycin’s selective inhibition profile. Overall, rapamycin’s established clinical use, detailed mechanistic understanding, and supportive preclinical evidence justify its further evaluation in IPF, yet its limitations highlight the need for continued innovation in targeted mTOR pathway modulation (ClinicalTrials.gov, 2011; Lawrence & Nho, 2018).

References
Aparicio, G., Calvo, M. B., Medina, V., Fernández, O., Jiménez, P., Lema, M., Figueroa, A., & Antón Aparicio, L. M. (2009). Comprehensive lung injury pathology induced by mTOR inhibitors. Clinical and Translational Oncology, 11, 499–510. https://doi.org/10.1007/s12094-009-0394-y

ClinicalTrials.gov. (2011). Double-blind placebo-controlled pilot study of sirolimus in idiopathic pulmonary fibrosis (IPF) (NCT01462006). https://clinicaltrials.gov/ct2/show/NCT01462006

Eley, J. (2018). Investigating the role of mTOR signalling in mediating the pro-fibrotic effects of TGF-β1. Unknown Journal, 234–236.

Gao, Y., Xu, X., Ding, K., Liang, Y., Jiang, D., & Dai, H. (2013). Rapamycin inhibits transforming growth factor β 1-induced fibrogenesis in primary human lung fibroblasts. Yonsei Medical Journal, 54(2), 437. https://doi.org/10.3349/ymj.2013.54.2.437

Lawrence, J., & Nho, R. (2018). The role of the mammalian target of rapamycin (mTOR) in pulmonary fibrosis. International Journal of Molecular Sciences, 19(3), 778. https://doi.org/10.3390/ijms19030778

Molina-Molina, M., Machahua-Huamani, C., Vicens-Zygmunt, V., Llatjós, R., Escobar, I., Sala-Llinás, E., Luburich-Hernaiz, P., Dorca, J., & Montes-Worboys, A. (2018). Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulmonary Medicine, 18, 62. https://doi.org/10.1186/s12890-018-0626-4

Patel, A. S., Lin, L.-Y., Geyer, A., Haspel, J., An, C., Cao, J., Rosas, I., & Morse, D. (2012). Autophagy in idiopathic pulmonary fibrosis. PLoS ONE, 7(7), e41394. https://doi.org/10.1371/journal.pone.0041394

Platé, M., Guillotin, D., & Chambers, R. C. (2020). The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis. European Respiratory Review, 29(158), 200269. https://doi.org/10.1183/16000617.0269-2020

Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., Taylor, A. R., Zinn, N., Redding, M., Forty, E. J., Hynds, R. E., Swanton, C., Karsdal, M., Maher, T. M., … Chambers, R. C. (2019). The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nature Communications, 10, 1132. https://doi.org/10.1038/s41467-018-07858-8
